Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 2
1975 28
1976 40
1977 86
1978 75
1979 110
1980 113
1981 145
1982 181
1983 207
1984 195
1985 223
1986 243
1987 220
1988 287
1989 258
1990 292
1991 249
1992 230
1993 225
1994 186
1995 178
1996 157
1997 164
1998 188
1999 177
2000 186
2001 193
2002 215
2003 211
2004 207
2005 256
2006 253
2007 229
2008 219
2009 209
2010 206
2011 179
2012 215
2013 216
2014 228
2015 199
2016 183
2017 169
2018 158
2019 150
2020 169
2021 159
2022 133
2023 118
2024 146
2025 44

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,822 results

Results by year

Filters applied: . Clear all
Page 1
A synthesis on the sub-lethal toxicity of atenolol, a beta-blocker, in teleost fish.
Ivantsova E, Martyniuk CJ. Ivantsova E, et al. Environ Toxicol Pharmacol. 2023 Sep;102:104236. doi: 10.1016/j.etap.2023.104236. Epub 2023 Jul 20. Environ Toxicol Pharmacol. 2023. PMID: 37481051 Review.
Heart rate appeared most sensitive to atenolol exposure relative to other endpoints. Data are lacking for behavioral responses to atenolol. ...Head kidney and liver may therefore be useful for detecting atenolol-induced effects. This review synthesizes knowle …
Heart rate appeared most sensitive to atenolol exposure relative to other endpoints. Data are lacking for behavioral responses to …
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Wadworth AN, Murdoch D, Brogden RN. Wadworth AN, et al. Drugs. 1991 Sep;42(3):468-510. doi: 10.2165/00003495-199142030-00007. Drugs. 1991. PMID: 1720383 Review.
Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours. ...Oral atenolol is used for preventing recurrence of supraventricular arrhythmias once control is achieved by intravenous administration of atenolol. ...
Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours. ...Oral atenolol is u …
Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.
Heel RC, Brogden RN, Speight TM, Avery GS. Heel RC, et al. Drugs. 1979 Jun;17(6):425-60. doi: 10.2165/00003495-197917060-00001. Drugs. 1979. PMID: 38096 Review.
Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity. ...There is no need for modification of dosage of atenolol in liver disease....
Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity. . …
Clinical pharmacokinetics of atenolol--a review.
Kirch W, Görg KG. Kirch W, et al. Eur J Drug Metab Pharmacokinet. 1982;7(2):81-91. doi: 10.1007/BF03188723. Eur J Drug Metab Pharmacokinet. 1982. PMID: 6749509 Review.
Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. ...Prolongation of elimination half life requires a dosage adjustment of atenolol in patients w …
Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the aten …
Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?
Karagiannis A, Mikhailidis DP, Kakafika AI, Tziomalos K, Athyros VG. Karagiannis A, et al. Curr Pharm Des. 2007;13(2):229-39. doi: 10.2174/138161207779313713. Curr Pharm Des. 2007. PMID: 17269930 Review.
However, recent meta-analyses of trials (either placebo-controlled or using drug comparisons) involving atenolol (a popular beta-blocker), have cast doubt on the suitability of atenolol as a first-line antihypertensive drug. We consider the mechanisms which might be …
However, recent meta-analyses of trials (either placebo-controlled or using drug comparisons) involving atenolol (a popular beta-bloc …
Atenolol and ischaemic heart disease: an overview.
Cruickshank JM, McAinsh J. Cruickshank JM, et al. Curr Med Res Opin. 1991;12(8):485-96. doi: 10.1185/03007999109111659. Curr Med Res Opin. 1991. PMID: 1764953 Review.
Data generated to date on the use of beta-blockers, especially atenolol, in ischaemic heart disease are reviewed and compared with the results available with the calcium antagonists. ...Atenolol, to date, is the only beta-blocker which has been demonstrated to have …
Data generated to date on the use of beta-blockers, especially atenolol, in ischaemic heart disease are reviewed and compared with th …
Atenolol in essential hypertension.
Myers MG, Lewis GR, Steiner J, Dollery CT. Myers MG, et al. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):502-7. doi: 10.1002/cpt1976195part1502. Clin Pharmacol Ther. 1976. PMID: 776487 Clinical Trial.
The effect of atenolol, a beta adrenoceptor autogonist, on arterial pressure in patients with benign essential hypertension has been investigated. Eighteen patients were started on atenolol, 75 mg/day; the dose was increased at 2-wk intervals to a maximum of 900 mg …
The effect of atenolol, a beta adrenoceptor autogonist, on arterial pressure in patients with benign essential hypertension has been …
A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients.
Xie H, Luo G, Zheng Y, Peng F, Xie L. Xie H, et al. Clin Exp Hypertens. 2017;39(5):421-426. doi: 10.1080/10641963.2016.1267188. Epub 2017 May 23. Clin Exp Hypertens. 2017. PMID: 28534649 Free article. Review.
Overall changes in PWV (weighted mean difference or WMD = 0.068, 95% confidence interval or CI: -0.487 to -0.623, P = 0.811) and peripheral systolic blood pressure (PSBP) (WMD = -1.281 mmHg, 95% CI: -6.936 to 4.375, P = 0.657) did not differ significantly between atenolol …
Overall changes in PWV (weighted mean difference or WMD = 0.068, 95% confidence interval or CI: -0.487 to -0.623, P = 0.811) and peripheral …
8,822 results